These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

446 related articles for article (PubMed ID: 11397884)

  • 21. Effect of long-term treatment with raloxifene on mammary density in postmenopausal women.
    Lasco A; Gaudio A; Morini E; Morabito N; Nicita-Mauro C; Catalano A; Denuzzo G; Sansotta C; Xourafa A; Macrì I; Frisina N
    Menopause; 2006; 13(5):787-92. PubMed ID: 16912660
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum levels of insulin-like growth factor binding proteins (IGFBP)-4 and -5 correlate with bone mineral density in growth hormone (GH)-deficient adults and increase with GH replacement therapy.
    Thorén M; Hilding A; Brismar T; Magnusson P; Degerblad M; Larsson L; Sääf M; Baylink DJ; Mohan S
    J Bone Miner Res; 1998 May; 13(5):891-9. PubMed ID: 9610754
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum insulin-like growth factor I (IGF-I), IGF-binding protein-1 and -3, and the acid-labile subunit as serum markers of body composition during growth hormone (GH) therapy in adults with GH deficiency.
    Thorén M; Hilding A; Baxter RC; Degerblad M; Wivall-Helleryd IL; Hall K
    J Clin Endocrinol Metab; 1997 Jan; 82(1):223-8. PubMed ID: 8989263
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Effects of amino acid solution and recombinant human growth hormone on growth hormone/insulin like growth factor-1 axis in rats with liver cirrhosis].
    Liang LJ; Luo SM; Hu WJ
    Zhonghua Wai Ke Za Zhi; 2005 Jun; 43(11):697-701. PubMed ID: 16008955
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of effects of the rise in serum testosterone by raloxifene and oral testosterone on serum insulin-like growth factor-1 and insulin-like growth factor binding protein-3.
    Duschek EJ; Gooren LJ; Netelenbos C
    Maturitas; 2005 Jul; 51(3):286-93. PubMed ID: 15978972
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Australian Multicenter Trial of Growth Hormone (GH) Treatment in GH-Deficient Adults.
    Cuneo RC; Judd S; Wallace JD; Perry-Keene D; Burger H; Lim-Tio S; Strauss B; Stockigt J; Topliss D; Alford F; Hew L; Bode H; Conway A; Handelsman D; Dunn S; Boyages S; Cheung NW; Hurley D
    J Clin Endocrinol Metab; 1998 Jan; 83(1):107-16. PubMed ID: 9435425
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Contrasting effects of oral and transdermal routes of estrogen replacement therapy on 24-hour growth hormone (GH) secretion, insulin-like growth factor I, and GH-binding protein in postmenopausal women.
    Weissberger AJ; Ho KK; Lazarus L
    J Clin Endocrinol Metab; 1991 Feb; 72(2):374-81. PubMed ID: 1991807
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNF-alpha, TGF-beta1 and bone turnover markers in the treatment of postmenopausal osteoporosis.
    Ozmen B; Kirmaz C; Aydin K; Kafesciler SO; Guclu F; Hekimsoy Z
    Eur Cytokine Netw; 2007 Sep; 18(3):148-53. PubMed ID: 17823083
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Raloxifene does not affect insulin sensitivity or glycemic control in postmenopausal women with type 2 diabetes mellitus: a randomized clinical trial.
    Andersson B; Johannsson G; Holm G; Bengtsson BA; Sashegyi A; Pavo I; Mason T; Anderson PW
    J Clin Endocrinol Metab; 2002 Jan; 87(1):122-8. PubMed ID: 11788634
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years.
    Jolly EE; Bjarnason NH; Neven P; Plouffe L; Johnston CC; Watts SD; Arnaud CD; Mason TM; Crans G; Akers R; Draper MW
    Menopause; 2003; 10(4):337-44. PubMed ID: 12851517
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The combination of insulin-like growth factor I and insulin-like growth factor-binding protein-3 reduces insulin requirements in insulin-dependent type 1 diabetes: evidence for in vivo biological activity.
    Clemmons DR; Moses AC; McKay MJ; Sommer A; Rosen DM; Ruckle J
    J Clin Endocrinol Metab; 2000 Apr; 85(4):1518-24. PubMed ID: 10770191
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Effect of recombinant human growth hormone on glucose metabolism in children with growth hormone deficiency].
    Liang L; Zou CC; Li Y; Wang CL; Jiang YJ; Dong GP; Fu JF; Wang XM
    Zhonghua Er Ke Za Zhi; 2006 Sep; 44(9):657-61. PubMed ID: 17217656
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of four weeks of supraphysiological growth hormone administration on the insulin-like growth factor axis in women and men. GH-2000 Study Group.
    Dall R; Longobardi S; Ehrnborg C; Keay N; Rosén T; Jørgensen JO; Cuneo RC; Boroujerdi MA; Cittadini A; Napoli R; Christiansen JS; Bengtsson BA; Sacca L; Baxter RC; Basset EE; Sönksen PH
    J Clin Endocrinol Metab; 2000 Nov; 85(11):4193-200. PubMed ID: 11095453
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age.
    Morales AJ; Nolan JJ; Nelson JC; Yen SS
    J Clin Endocrinol Metab; 1994 Jun; 78(6):1360-7. PubMed ID: 7515387
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of intranasal 17beta-estradiol on bone turnover and serum insulin-like growth factor I in postmenopausal women.
    Garnero P; Tsouderos Y; Marton I; Pelissier C; Varin C; Delmas PD
    J Clin Endocrinol Metab; 1999 Jul; 84(7):2390-7. PubMed ID: 10404809
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The impact of dose and route of estrogen administration on the somatotropic axis in normal women.
    Lissett CA; Shalet SM
    J Clin Endocrinol Metab; 2003 Oct; 88(10):4668-72. PubMed ID: 14557438
    [TBL] [Abstract][Full Text] [Related]  

  • 37. IGF-I and IGF binding protein-3 levels during initial GH dosage step-up are indicators of GH sensitivity in GH-deficient children and short children born small for gestational age.
    Ranke MB; Traunecker R; Martin DD; Schweizer R; Schwarze CP; Wollmann HA; Binder G
    Horm Res; 2005; 64(2):68-76. PubMed ID: 16113581
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of raloxifene on IGF-I and IGFBP-3 in postmenopausal women with breast cancer.
    Torrisi R; Baglietto L; Johansson H; Veronesi G; Bonanni B; Guerrieri-Gonzaga A; Ballardini B; Decensi A
    Br J Cancer; 2001 Dec; 85(12):1838-41. PubMed ID: 11747323
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nutritional and endocrine-metabolic aberrations in women with functional hypothalamic amenorrhea.
    Laughlin GA; Dominguez CE; Yen SS
    J Clin Endocrinol Metab; 1998 Jan; 83(1):25-32. PubMed ID: 9435412
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differential effects of raloxifene and estrogen on body composition in growth hormone-replaced hypopituitary women.
    Birzniece V; Meinhardt UJ; Gibney J; Johannsson G; Armstrong N; Baxter RC; Ho KK
    J Clin Endocrinol Metab; 2012 Mar; 97(3):1005-12. PubMed ID: 22170716
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.